DZ Bank Knock-Out SNW/ DE000DQ6E0M9 /
2024-08-30 9:05:38 AM | Chg.+0.08 | Bid4:05:09 PM | Ask4:05:09 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
2.26EUR | +3.67% | 2.27 Bid Size: 60,000 |
2.28 Ask Size: 60,000 |
SANOFI SA INHABER ... | 79.1025 EUR | 2078-12-31 | Call |
GlobeNewswire
08-14
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
GlobeNewswire
08-13
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
08-12
MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter ...
GlobeNewswire
08-08
Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free sur...
GlobeNewswire
08-07
Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
GlobeNewswire
08-06
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D ...
GlobeNewswire
08-01
Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
07-31
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2...
GlobeNewswire
07-25
Press Release: Online availability of Sanofi’s half-year financial report for 2024
GlobeNewswire
07-25
Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded
GlobeNewswire
07-24
US Hematologists Express High Unmet Need in Treatments for Warm Autoimmune Hemolytic Anemia and Cold...
GlobeNewswire
07-18
Takeda’s Eohilia Sees Strong Early Adoption and Growth Potential in Eosinophilic Esophagitis, Accord...
GlobeNewswire
07-17
Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transfor...
GlobeNewswire
07-12
FluGen’s Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults Shows ...
GlobeNewswire
07-11
Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Upd...
GlobeNewswire
07-08
Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review ...
GlobeNewswire
07-03
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients...